MANNKIND CORP (MNKD)       4.82  +0.12 (+2.55%)

4.82  +0.12 (+2.55%)

US56400P7069 - Common Stock - After market: 4.82 0 (0%)

MANNKIND CORP4.82

NASDAQ:MNKD (12/8/2022, 4:58:07 PM)+0.12 (+2.55%)

After market: 4.82 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-08 2022-11-08/bmo Earnings (Next) 02-22 2023-02-22
Ins Owners 2.62% Inst Owners 49.36%
Market Cap 1.27B Shares 263.20M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85
IPO 07-28 2004-07-28

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

MNKD Daily chart

Company Profile

MannKind Corp. operates as a biopharmaceutical company. The company is headquartered in Danbury, Connecticut and currently employs 348 full-time employees. The company went IPO on 2004-07-28. The firm is focused on the development and commercialization of inhaled therapeutic products for diabetes and orphan lung diseases, such as pulmonary arterial hypertension. The Company’s lead product is Afrezza Inhalation Powder, which is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Technosphere is a drug delivery platform that allow the oral inhalation of a range of therapeutics.

Company Info

MANNKIND CORP

1 Casper Street

Danbury CONNECTICUT 91362

P: 18186615000.0

CEO: Michael E. Castagna

Employees: 348

Website: https://mannkindcorp.com/

MNKD News

News Imagea month ago - MannKindMannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting

Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous...

News Imagea month ago - MannKindMannKind to Present Two Posters at 22nd Annual Diabetes Technology MeetingNews Imagea month ago - The Motley FoolMannKind Corporation (MNKD) Q3 2022 Earnings Call Transcript

MNKD earnings call for the period ending September 30, 2022.

News Imagea month ago - MannKindMannKind Corporation Reports 2022 Third Quarter Financial Results

Conference Call to Begin Today at 9:00 a.m. (ET)

News Imagea month ago - MannKindMannKind Corporation Reports 2022 Third Quarter Financial Results

Conference Call to Begin Today at 9:00 a.m. (ET)...

News Imagea month ago - MannKindMannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 third quarter...

MNKD Twits

Here you can normally see the latest stock twits on MNKD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example